MI-192 is a selective HDAC2 and HDAC3 inhibitor with IC 50 s of 30 nM and 16 nM, respectively. MI-192 is more selective for HDAC2/3 than other HDAC isomers.MI-192 induces myeloid leukaemic cells apoptosis. MI-192 has potential use in leukaemia and anti-stroke [1] [2].

MI-192, at concentrations ranging from 0.15 to 1 μM over a period of 72 hours, both induces differentiation and exerts cytotoxic effects through apoptosis promotion in the acute myeloid leukemia cell lines U937, HL60, and Kasumi-1 [1]. Specifically, apoptosis analysis revealed that MI-192, at concentrations of 150 nM, 300 nM, 500 nM, and 1 μM, significantly induced apoptosis in HL60 and Kasumi-1 cells after a 72-hour incubation [1].

MI-192 (40 mg/kg; i.p.; once a day for 3 days) demonstrates neuroprotective effects in mice with photothrombotic stroke (PTS). Administered to adult male outbred CD-1 mice (20-25 g) with PTS, MI-192 significantly reduced the volume of the PTS-induced infarction in the brain, improved forelimb functional symmetry, lowered PTS-induced apoptosis and α-tubulin acetylation—a marker of stable microtubules—and enhanced GAP-43 expression in the cerebral cortex of the affected hemisphere.